个体化短疗程抗生素治疗呼吸机相关性肺炎的非劣效性随机试验
这项在尼泊尔、新加坡和泰国39个ICU开展的多中心随机开放标签非劣效性试验纳入461例呼吸机相关性肺炎成人患者,比较个体化短疗程(中位6天)与常规长疗程(中位14天)抗生素治疗。60天死亡或肺炎复发复合终点短疗程组41% vs 常规组44%,风险差-3%(单侧95%CI -∞至5%),达到非劣效性但未证实优效;短疗程组抗生素副作用显著减少(8% vs 38%)。
要点
- 个体化短疗程抗生素(中位6天)治疗VAP在60天死亡或复发风险上非劣于常规长疗程(中位14天)。
- 短疗程组抗生素副作用发生率8%,显著低于常规组的38%。
- 该策略可减少抗生素使用和副作用负担,适用于高资源和资源有限环境。
核心结论
- 在呼吸机相关性肺炎成人患者中,以临床反应为指导的个体化短疗程抗生素治疗在60天死亡和肺炎复发方面非劣于长疗程治疗,且显著减少抗生素使用和副作用。
研究设计与样本
- 4期、多中心、个体随机、开放标签、层级非劣效-优效性试验,在尼泊尔、新加坡和泰国的6家医院39个ICU开展。
- 纳入年龄≥18岁、符合美国CDC国家医疗安全网络VAP标准、机械通气≥48小时且接受培养指导抗生素治疗的成人患者。
- 共纳入461例患者,随机分配至短疗程组(n=232)或常规组(n=229);中位年龄64岁(IQR 51-74),女性181例(39%)。
- 意向性治疗分析纳入460例(短疗程组231例,常规组229例),符合方案集纳入435例。
- 主要终点为60天死亡或肺炎复发复合终点,非劣效界值预设为12%。
主要发现
- 短疗程组VAP指数发作的中位抗生素疗程为6天(IQR 5-7),常规组为14天(IQR 10-21)。
- 短疗程组231例中95例(41%)达到主要终点,常规组229例中100例(44%)达到主要终点,风险差-3%(单侧95%CI -∞至5%)。
- 符合方案集分析结果与意向性治疗分析相似,达到非劣效性,但未证实优效性。
关键数值与推荐
- 非劣效界值预设为12%,需在意向性治疗和符合方案集分析中均满足。
- 短疗程定义为≤7天且可短至3-5天,常规治疗定义为≥8天,具体时长由主管临床医生决定。
- 主要终点为60天死亡或肺炎复发复合终点。
临床怎么用
- 对于呼吸机相关性肺炎成人患者,可根据临床反应(发热消退48小时和血流动力学稳定)采用个体化短疗程抗生素治疗,短至3-5天。
- 该策略可减少抗生素暴露和副作用,并可能有助于降低抗生素耐药风险。
局限性
- 开放标签设计,临床医生未设盲,但主要终点由独立评估者判定且患者设盲。
- 研究在尼泊尔、新加坡和泰国开展,结果外推需考虑不同地区病原学和抗菌药物管理差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ventilator-associated pneumonia (VAP) is associated with increased mortality, prolonged hospitalisation, excessive antibiotic use and, consequently, increased antimicrobial resistance. In this phase 4, randomised trial, we aimed to establish whether a pragmatic, individualised, short-course antibiotic treatment strategy for VAP was non-inferior to usual care. METHODS: We did an individually randomised, open-label, hierarchical non-inferiority-superiority trial in 39 intensive care units in six hospitals in Nepal, Singapore, and Thailand. We enrolled adults (age ≥18 years) who met the US Centers for Disease Control and Prevention National Healthcare Safety Network criteria for VAP, had been mechanically ventilated for 48 h or longer, and were administered culture-directed antibiotics. In culture-negative cases, empirical antibiotic choices were made depending on local hospital antibiograms reported by the respective microbiology laboratories or prevailing local guidelines. Participants were assessed until fever resolution for 48 h and haemodynamic stability, then randomly assigned (1:1) to individualised short-course treatment (≤7 days and as short as 3-5 days) or usual care (≥8 days, with precise durations determined by the primary clinicians) via permuted blocks of variable sizes (8, 10, and 12), stratified by study site. Independent assessors for recurrent pneumonia and participants were masked to treatment allocation, but clinicians were not. The primary outcome was a 60-day composite endpoint of death or pneumonia recurrence. The non-inferiority margin was prespecified at 12% and had to be met by analyses based on both intention-to-treat (all study participants who were randomised) and per-protocol populations (all randomised study participants who fulfilled the eligibility criteria, met fitness criteria for antibiotic discontinuation, and who received antibiotics for the duration specified by their allocation group). This study is registered with ClinicalTrials.gov, number NCT03382548. FINDINGS: Between May 25, 2018, and Dec 16, 2022, 461 patients were enrolled and randomly assigned to the short-course treatment group (n=232) or the usual care group (n=229). Median age was 64 years (IQR 51-74) and 181 (39%) participants were female. 460 were included in the intention-to-treat analysis after excluding one withdrawal (231 in the short-course group and 229 in the usual care group); 435 participants received the allocated treatment and fulfilled eligibility criteria, and were included in the per-protocol population. Median antibiotic treatment duration for the index episodes of VAP was 6 days (IQR 5-7) in the short-course group and 14 days (10-21) in the usual care group. 95 (41%) of 231 participants in the short-course group met the primary outcome, compared with 100 (44%) of 229 in the usual care group (risk difference -3% [one-sided 95% CI -∞ to 5%]). Results were similar in the per-protocol population. Non-inferiority of short-course antibiotic treatment was met in the analyses, although superiority compared with usual care was not established. In the per-protocol population, antibiotic side-effects occurred in 86 (38%) of 224 in the usual care group and 17 (8%) of 211 in the short-course group (risk difference -31% [95% CI -37 to -25%; p<0·0001]). INTERPRETATION: In this study of adults with VAP, individualised shortened antibiotic duration guided by clinical response was non-inferior to longer treatment durations in terms of 60-day mortality and pneumonia recurrence, and associated with substantially reduced antibiotic use and side-effects. Individualised, short-course antibiotic treatment for VAP could help to reduce the burden of side-effects and the risk of antibiotic resistance in high-resource and resource-limited settings. FUNDING: UK Medical Research Council; Singapore National Medical Research Council. TRANSLATIONS: For the Thai and Nepali translations of the abstract see Supplementary Materials section.
引用
- Mo Y, Booraphun S, Li AY, et al. Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial. Lancet Respir Med. 2024. PMID: 38272050. doi:10.1016/S2213-2600(23)00418-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。